The benefits people search for — more lean muscle, better sleep, faster recovery, firmer skin, higher libido, a general anti-aging effect — come from seller pages, not from a drug label. Sermorelin has no current label of its own. So the honest version of “what are the benefits” is a list of outcomes that were measured in people, and for each one, which people it happened to. That second half is where most of the surprise is.
One benefit held in both sexes
Skin thickness. In the only placebo-controlled adult trial — nineteen adults aged 55 to 71, five months, published in 1997 [1] — skin thickness improved in the men and in the women, at P < 0.05. It is the least-marketed of the six claims and the only one with a result that did not depend on which half of the trial you were in.
Three benefits held in men only
Lean body mass, general well-being and libido all improved in the nine men and did not change in the ten women. Libido carried the strongest single number in the study, at P < 0.01. Those three outcomes are doing most of the work in sermorelin marketing, and all three come with a population attached that the marketing rarely mentions. If you are a woman reading a page that promises lean mass and drive, what the trial found in women specifically is the relevant page, and the lean-mass result on its own has the detail for men.
Two things were measured and did not move
Sleep quality and bone mineral density were both tested and both unchanged, in both sexes. Sleep is worth dwelling on because it is among the most heavily advertised sermorelin benefits and it is not an untested claim — it is a tested one that failed. The distinction matters: an untested claim might still be true, while a tested one that produced no change has been given its chance. The wider sleep literature on GHRH is more interesting than the sermorelin result, and it still does not rescue the claim.
One benefit was never measured at all
Recovery. It is advertised constantly and it does not appear as an outcome in the trial. There is no result to report, positive or negative. The ranking of all six claims against what was actually found is in the claim-by-claim breakdown.
What sermorelin definitely does
Underneath the benefit claims is one effect nobody disputes. Sermorelin is a GHRH analog: it signals the pituitary to release more of your own growth hormone, and the downstream markers follow. IGF-1 and IGFBP-3 rose within about two weeks, in everyone [1]. A companion report on the same nineteen people also examined immune measures [2].
That is a real, reproducible biological effect, and it is not the same thing as a benefit. A lab value moving as expected confirms the drug is active in you; it does not confirm that anything you would notice has changed, which is the whole distinction drawn in the biomarker-versus-outcome comparison.
Reading a benefits list with the population attached
Every figure above comes from the same nineteen people. There is no second trial confirming any of it, and the immune paper is a companion report on that same cohort rather than an independent replication. Nineteen is a small number, five months is a short time, and 55 to 71 is a narrow age band — so the sex split should be read as what the study found, not as a settled fact about men and women.
The practical version is short. One benefit has support in both sexes. Three have support in men. Two were tested and did not happen. One was never tested. Any page presenting those seven outcomes as a single flat list of benefits is describing marketing rather than evidence.